Why Cardlytics, Inc.’s (CDLX) Stock Is Up 5.52%
As of Friday, April 17, Cardlytics, Inc.’s CDLX share price has surged by 5.52%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. The company provides Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data from merchant data partners, including product-level purchase data to enable marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. Cardlytics, Inc. was incorporated in 2008 and is headquartered in Atlanta, Georgia.
Commentary & Analysis
Why Cardlytics, Inc.’s (CDLX) Stock Is Down 5.93%
As of Thursday, April 16, Cardlytics, Inc.’s CDLX share price has dipped by 5.93%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Cardlytics, Inc.’s (CDLX) Stock Is Up 6.09%
As of Tuesday, April 14, Cardlytics, Inc.’s CDLX share price has surged by 6.09%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cardlytics, Inc.’s (CDLX) Stock Is Down 5.35%
As of Friday, April 10, Cardlytics, Inc.’s CDLX share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Cardlytics, Inc.’s (CDLX) Stock Is Down 6.28%
As of Wednesday, April 08, Cardlytics, Inc.’s CDLX share price has dipped by 6.28%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CDLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.6 | $411.8 | 7% |
|
| Shares Out (Mil) | 5.9 | 41.6 | 16% |
|
| Institutional Ownership | 83.6% | 50.0% | 52% |
|
| Float (Mil) | 5.2 | 35.5 | 12% |
|
| Beta | na | 0.96 | na |
|
| Avg Daily Volume (000s) | 84 | 161 | 34% |
|
| Price Change (52-week) |
(88.4%) | 64.3% | 6% |
|
| Growth | CDLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.5% | 2.6% | 34% |
|
| Net Income (5yr) | (13.3%) | (4.8%) | 26% |
|
| EPS (5yr) | 0.9% | 5.0% | 32 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.4%) | (16.1%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($1.150) | ($2.685) | ($3.955) | |
| Month Ago EPS | ($0.845) | ($2.305) | ($3.295) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.845) | ($2.305) | ($3.295) | |
| Year/Year Chg | (8.7%) | (86.2%) | na | |
| Financials | CDLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $171 | $517 | 30% |
|
| Net Income (TTM) (Mil) | ($37) | ($2) | 19% |
|
| EPS (TTM) | ($6.472) | $0.000 | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | $57 | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $0 | na |
|
| Long-Term Debt (Q1) (Mil) | $199 | $159 | 50% |
|
| Enterprise Value (Q1) (Mil) | $183 | $992 | 26% |
|
| Valuation | CDLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.30 | na |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | CDLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 49.6% | 43.4% | 61% |
|
| Net Margin | (21.4%) | (1.2%) | 16% |
|
| ROA | (14.0%) | (0.9%) | 22% |
|
| ROE | 263.7% | 0.0% | 99% |
|
| Liabilities to Assets | 110.1% | 59.6% | 96% |
|
| F-Score | 4 | 4 | 33% |
|
Cardlytics, Inc. did not pass any screens on 11/10/2026.
